Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03278002 · ClinicalTrials.gov registry record
A Registry for Patients Taking Uptravi
A clinical trial of Pulmonary Arterial Hypertension, sponsored by Actelion.
- Completed
- Registry status
- 800
- Enrollment target
- 20
- Study locations
NCT03278002: Completed study of Pulmonary Arterial Hypertension, sponsored by Actelion.
NCT03278002 is a study of Pulmonary Arterial Hypertension that has completed, run by Actelion. The registered enrollment target is 800 participants, above the 450-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (78% higher). The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03278002, a study of Pulmonary Arterial Hypertension, has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- 800 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into the registry.
Primary Outcome
To describe demographics and disease characteristics of patients treated with Uptravi.
Conditions Studied
Study Locations (20)
Florida
- Florida Lung Asthma and Sleep Specialists - Celebration
- Broward Pulmonary and Sleep - Fort Lauderdale
- University of Florida, HSC - Gainesville
- West Pasco Pulmonary Associates - Hudson
- University of Florida-Jacksonville College of Medicine - Jacksonville
- Central Florida Pulmonary Group - Orlando
- University of South Florida - Tampa
California
- University of California San Diego - La Jolla
- University of Southern California - Los Angeles
- VA Greater Los Angeles Healthcare Center - Los Angeles
- UCSF Medical Center - San Francisco
- Santa Barbara Cottage Hospital - Santa Barbara
- Lundquist Institute for Biomedical Innovation at Harbor-UCLA - Torrance
Arizona
- Pulmonary Associates - Phoenix
- Cardioivascular Consultants, Ltd. - Phoenix
- University of Arizona-Clinical Translational and Regenerative Medicine - Tucson
Colorado
- University of Colorado - Aurora
- National Jewish Health - Denver
- Banner Health Research Institute - Greeley
Alabama
- University of South Alabama - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2016-11-01 |
| Est. Completion | 2021-09-21 |
What the finished NCT03278002 record still lists
NCT03278002 is an observational study that tracks outcomes without assigning an intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, above the 450-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (78% higher).
The record links to 1 condition, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 0 interventions.
NCT03278002 names 20 study sites across 5 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT03278002 about?
NCT03278002 is a clinical study titled "A Registry for Patients Taking Uptravi". This is a US multi-center, prospective, real world, observational drug registry enrolling patients actively treated with Uptravi. Participating patients will be followed prospectively for a maximum of 18 months from the date of enrollment into the registry.
What is the current status of trial NCT03278002?
This trial is currently completed. The enrollment target is 800 participants. The study started on 2016-11-01. Estimated completion is 2021-09-21.
What conditions does trial NCT03278002 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension.
Who is sponsoring clinical trial NCT03278002?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03278002 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03278002's enrollment target sits among peer trials
800 9th of 63 higher than 55 of 63 other Pulmonary Arterial Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Arterial Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
-
The MObile Health InterVEntion in Pulmonary Arterial Hypertension (MOVE PAH) Study
RECRUITING · NA
-
Trial to Evaluate Parenteral Treprostinil and Riociguat on Right Ventriculo-vascular Coupling and Morphology in Those With Advanced PAH
RECRUITING · Phase 3
-
A Placebo-controlled, Randomized Clinical Trial to Assess the Safety, Feasibility, and Pharmacokinetics of Microbiota Transplant Therapy With Antibiotic Preconditioning and Fiber Supplementation in Patients With Pulmonary Arterial Hypertension
RECRUITING · Phase 1
-
129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)
RECRUITING · Phase 2
-
Pulmonary Hypertension SOLAR
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI